Ayisha Sharma - Endpoints News

about the author As a news reporter, Ayisha Sharma focuses on the UK and Europe biopharma space and has an interest in psychiatric drug R&D. Ayisha joined Endpoints from Scrip, where she spent nearly two years covering the commercial implications of clinical trial readouts, drug approvals and industry dealmaking. Prior to this, she was an investigative journalist at GlobalData Insights.

Ayisha holds an MA in Philosophy from University College London as well as a diploma in multimedia journalism. In her spare time, she enjoys running, yoga and watching horror films. author articles Baby KJ's gene-editing drug cost $1.65M to make, Fyodor Urnov says Roche says Carmot-acquired shot delivers Phase 2 win in overweight patients with diabetes Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win Skyhawk says its Huntington’s drug improved symptoms in extension to Phase 1/2 trial GSK strikes deal for Chimagen’s T cell engager for blood cancer AstraZeneca’s next-gen SERD disappoints in untreated advanced breast cancer BridgeBio Oncology slides as it tightens the scope of its KRAS program Sanofi spells out asthma data, AstraZeneca details COPD win at #ERS26 Roivant reports Phase 2 win for lung disease drug that it got from Bayer Beam says AATD base editing data hold up after one year Ionis wins FDA clearance for Alexander disease drug, company's first solo neurology approval Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial Roche bets $1B+ on DualityBio's ADC tech to tackle payload resistance Generate Biomedicines discloses early respiratory drug data after congress poster leak Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data Regenxbio hit with another clinical hold for Hunter syndrome gene therapy Roche bets up to $2.3B on Hanmi’s early-stage muscle-building